Technical Analysis for ONCE - Spark Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 110.6 0.00% 0.00
ONCE closed unchanged on Tuesday, April 23, 2019, on 25 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Up Up Down
See historical ONCE trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 118.53%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 118.53%
Multiple of Ten Bullish Other 118.53%
Overbought Stochastic Strength 118.53%
Down 3 Days in a Row Weakness 118.53%
Earnings Movers Other 117.33%
Multiple of Ten Bullish Other 117.33%
Weak + Overbought Other 117.33%
Inside Day Range Contraction 117.33%
Overbought Stochastic Strength 117.33%

Older signals for ONCE ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company is developing SPK-RPE65, which is in Phase III clinical trial for the treatment of inherited retinal dystrophies, a group of rare blinding conditions caused by non-sex linked, or autosomal recessive, mutations in the RPE65 gene. It is also developing SPK-CHM for the treatment of choroideremia; and preclinical programs in development for the treatment of hemophilia A and neurodegenerative diseases, as well as a pipeline of product candidates targeting rare blinding conditions. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B; and development and manufacturing collaboration with Genable Technologies Limited for the manufacture and provision of development advice in the development of Genable's therapeutic product candidate, GT038, to treat rhodopsin-linked autosomal dominant retinitis pigmentosa. The company was founded in 2013 and is based in Philadelphia, Pennsylvania.
Biology Emerging Technologies Gene Therapy Molecular Biology Medical Genetics Blindness Neurodegenerative Diseases Retinitis Pigmentosa Gene Delivery Treatment Of Hemophilia Gene Therapy Products Genetic Diseases Hemophilia A Choroideremia Genetic Disorder Hemophilia B
Is ONCE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 5 bullish, 0 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 114.2
52 Week Low 34.53
Average Volume 2,374,125
200-Day Moving Average 65.2633
50-Day Moving Average 101.7266
20-Day Moving Average 112.344
10-Day Moving Average 111.308
Average True Range 0.9675
ADX 50.68
+DI 32.1367
-DI 21.9827
Chandelier Exit (Long, 3 ATRs ) 111.2075
Chandelier Exit (Short, 3 ATRs ) 112.7625
Upper Bollinger Band 114.8446
Lower Bollinger Band 109.8434
Percent B (%b) 0.15
BandWidth 4.451684
MACD Line 1.9624
MACD Signal Line 3.3279
MACD Histogram -1.3655
Fundamentals Value
Market Cap 3.46 Billion
Num Shares 31.3 Million
EPS -6.39
Price-to-Earnings (P/E) Ratio -17.31
Price-to-Sales 124.29
Price-to-Book 11.08
PEG Ratio -0.59
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 111.44
Resistance 3 (R3) 111.43 111.15 111.30
Resistance 2 (R2) 111.15 110.93 111.15 111.25
Resistance 1 (R1) 110.87 110.80 110.73 110.88 111.21
Pivot Point 110.59 110.59 110.52 110.59 110.59
Support 1 (S1) 110.31 110.37 110.17 110.32 109.99
Support 2 (S2) 110.03 110.24 110.03 109.95
Support 3 (S3) 109.75 110.03 109.90
Support 4 (S4) 109.76